💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Sotagliflozin

CHEMBL3039507 Phase 4 承認済み Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
424.9 g/mol
LogP
3.2
Phase
4

Sotagliflozin is a dual sodium-glucose cotransporter 1 and 2 (SGLT1/SGLT2) inhibitor used for the reduction of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure and type 2 diabetes with chronic kidney disease. By inhibiting both intestinal SGLT1 and renal SGLT2, it reduces glucose absorption and renal glucose reabsorption, lowers blood glucose, and reduces sodium retention with accompanying reductions in heart failure risk. Its dual mechanism provides complementary glycosuric and cardiorenal benefits.

分子量

424.9000 g/mol

LogP

3.20

TPSA

104.00 Ų

リピンスキーの五則

適合

治療領域

Chronic Kidney Disease Deep Vein Thrombosis / Pulmonary Embolism Type 2 Diabetes Heart Failure Cardiovascular Disease

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCOc1ccc(Cc2cc([C@@H]3O[C@H](SC)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1

                

                

                
                

                    
InChI

                    
InChI=1S/C21H25ClO5S/c1-3-26-15-7-4-12(5-8-15)10-14-11-13(6-9-16(14)22)20-18(24)17(23)19(25)21(27-20)28-2/h4-9,11,17-21,23-25H,3,10H2,1-2H3/t17-,18-,19+,20+,21-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C21H25ClO5S

                    

                    
                    

                        
HBD / HBA

                        
3 / 6

                    

                    
                    

                        
回転可能結合数

                        
6

                    

                    
                    
                    

                        
重原子数

                        
28

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
Sotagliflozin is a dual sodium-glucose cotransporter 1 and 2 (SGLT1/SGLT2) inhibitor used for the reduction of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure and type 2 diabetes with chronic kidney disease. By inhibiting both intestinal SGLT1 and renal SGLT2, it reduces glucose absorption and renal glucose reabsorption, lowers blood glucose, and reduces sodium retention with accompanying reductions in heart failure risk. Its dual mechanism provides complementary glycosuric and cardiorenal benefits.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Sotagliflozin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3039507.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 24831714.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.